Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2026)

Denali Therapeutics (DNLI) has 4 years of Interest & Investment Income data on file, last reported at $8.9 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 29.34% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $39.2 million, a 36.08% decrease from a year earlier, with the FY2025 full-year figure at $42.9 million, down 33.62% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $8.9 million, roughly flat from $8.9 million in the prior quarter.
• Over the last five years, Interest & Investment Income for DNLI reached as high as $17.6 million in Q2 2024 and fell as low as $8.9 million in Q1 2026.
• Historically, Interest & Investment Income has averaged $12.9 million across 4 years, with a median of $12.9 million in 2023.
• Across the five-year window, Interest & Investment Income soared 44.22% in 2024 and tumbled 41.18% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $13.1 million in 2023, then gained by 15.48% to $15.2 million in 2024, then tumbled by 41.18% to $8.9 million in 2025, then declined by 0.09% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $8.9 million in Q1 2026, $8.9 million in Q4 2025, and $10.5 million in Q3 2025.